Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters

Departments of Immunology 1 and Cancer Genetics 2 , Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK 3 Author for correspondence: Peter Stern. Fax +44...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of general virology 1999-12, Vol.80 (12), p.3233-3240
Hauptverfasser: Brady, Claire S, Duggan-Keen, Margaret F, Davidson, Judith A, Varley, Jenny M, Stern, Peter L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3240
container_issue 12
container_start_page 3233
container_title Journal of general virology
container_volume 80
creator Brady, Claire S
Duggan-Keen, Margaret F
Davidson, Judith A
Varley, Jenny M
Stern, Peter L
description Departments of Immunology 1 and Cancer Genetics 2 , Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK 3 Author for correspondence: Peter Stern. Fax +44 161 446 3109. e-mail pstern{at}picr.man.ac.uk Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.
doi_str_mv 10.1099/0022-1317-80-12-3233
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69293975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17479339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-b852dd2132e2f2d533175b69cb5bab90d351867cd7a12e2cad3423840ba01c2f3</originalsourceid><addsrcrecordid>eNqFkU9r3DAQxUVpaTZpv0EJOhV6cKr_tnorS5oEAr20ZzGW5ayCLbmSvCGQD19tN4TcehoYfu8N8x5Cnyi5oETrr4Qw1lBO26YjDWUNZ5y_QRsqlGxYBd6izQtygk5zvieECiHb9-iEEqlaJdUGPV2vMwS8wOKnKc6w92nNuDwuDlOFLxXeQ_IQSsY-YOvS3luYsIVkfaj4N5zcBMXHkHd-wSXiXcwF37ngird4BFtiyhjCgO3kwz_xAglmV1zKH9C7EabsPj7PM_T7x-Wv7XVz-_PqZvv9trGCitL0nWTDwChnjo1skLx-JHulbS976DUZuKSdau3QAq2IhYELxjtBeiDUspGfoc9H3yXFP6vLxcw-WzdNEFxcs1Gaaa5b-V-QtqLVnOsKiiNoU8w5udEsyc-QHg0l5lCPOWRvDtmbrm6YOdRTZefP_ms_u-GV6NhHBb4cgZ2_2z345EyNcvb1Su-jqeW8MvsLE3-agQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17479339</pqid></control><display><type>article</type><title>Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters</title><source>MEDLINE</source><source>Microbiology Society</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Brady, Claire S ; Duggan-Keen, Margaret F ; Davidson, Judith A ; Varley, Jenny M ; Stern, Peter L</creator><creatorcontrib>Brady, Claire S ; Duggan-Keen, Margaret F ; Davidson, Judith A ; Varley, Jenny M ; Stern, Peter L</creatorcontrib><description>Departments of Immunology 1 and Cancer Genetics 2 , Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK 3 Author for correspondence: Peter Stern. Fax +44 161 446 3109. e-mail pstern{at}picr.man.ac.uk Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.</description><identifier>ISSN: 0022-1317</identifier><identifier>EISSN: 1465-2099</identifier><identifier>DOI: 10.1099/0022-1317-80-12-3233</identifier><identifier>PMID: 10567656</identifier><language>eng</language><publisher>England: Soc General Microbiol</publisher><subject>Adult ; Aged ; Aged, 80 and over ; E6 protein ; Female ; Genes, MHC Class I ; Genes, MHC Class II ; Genes, p53 ; Genetic Variation ; histocompatibility antigen HLA ; Human papillomavirus 16 ; Humans ; Middle Aged ; Neoplasm Staging ; Oncogene Proteins, Viral - genetics ; p53 gene ; Papillomaviridae - classification ; Papillomaviridae - genetics ; Papillomavirus Infections - virology ; Point Mutation ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Repressor Proteins ; Sequence Analysis, DNA ; Tumor Virus Infections - virology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology</subject><ispartof>Journal of general virology, 1999-12, Vol.80 (12), p.3233-3240</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-b852dd2132e2f2d533175b69cb5bab90d351867cd7a12e2cad3423840ba01c2f3</citedby><cites>FETCH-LOGICAL-c414t-b852dd2132e2f2d533175b69cb5bab90d351867cd7a12e2cad3423840ba01c2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3746,3747,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10567656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brady, Claire S</creatorcontrib><creatorcontrib>Duggan-Keen, Margaret F</creatorcontrib><creatorcontrib>Davidson, Judith A</creatorcontrib><creatorcontrib>Varley, Jenny M</creatorcontrib><creatorcontrib>Stern, Peter L</creatorcontrib><title>Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters</title><title>Journal of general virology</title><addtitle>J Gen Virol</addtitle><description>Departments of Immunology 1 and Cancer Genetics 2 , Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK 3 Author for correspondence: Peter Stern. Fax +44 161 446 3109. e-mail pstern{at}picr.man.ac.uk Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>E6 protein</subject><subject>Female</subject><subject>Genes, MHC Class I</subject><subject>Genes, MHC Class II</subject><subject>Genes, p53</subject><subject>Genetic Variation</subject><subject>histocompatibility antigen HLA</subject><subject>Human papillomavirus 16</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncogene Proteins, Viral - genetics</subject><subject>p53 gene</subject><subject>Papillomaviridae - classification</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus Infections - virology</subject><subject>Point Mutation</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic</subject><subject>Repressor Proteins</subject><subject>Sequence Analysis, DNA</subject><subject>Tumor Virus Infections - virology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - virology</subject><issn>0022-1317</issn><issn>1465-2099</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9r3DAQxUVpaTZpv0EJOhV6cKr_tnorS5oEAr20ZzGW5ayCLbmSvCGQD19tN4TcehoYfu8N8x5Cnyi5oETrr4Qw1lBO26YjDWUNZ5y_QRsqlGxYBd6izQtygk5zvieECiHb9-iEEqlaJdUGPV2vMwS8wOKnKc6w92nNuDwuDlOFLxXeQ_IQSsY-YOvS3luYsIVkfaj4N5zcBMXHkHd-wSXiXcwF37ngird4BFtiyhjCgO3kwz_xAglmV1zKH9C7EabsPj7PM_T7x-Wv7XVz-_PqZvv9trGCitL0nWTDwChnjo1skLx-JHulbS976DUZuKSdau3QAq2IhYELxjtBeiDUspGfoc9H3yXFP6vLxcw-WzdNEFxcs1Gaaa5b-V-QtqLVnOsKiiNoU8w5udEsyc-QHg0l5lCPOWRvDtmbrm6YOdRTZefP_ms_u-GV6NhHBb4cgZ2_2z345EyNcvb1Su-jqeW8MvsLE3-agQ</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>Brady, Claire S</creator><creator>Duggan-Keen, Margaret F</creator><creator>Davidson, Judith A</creator><creator>Varley, Jenny M</creator><creator>Stern, Peter L</creator><general>Soc General Microbiol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>19991201</creationdate><title>Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters</title><author>Brady, Claire S ; Duggan-Keen, Margaret F ; Davidson, Judith A ; Varley, Jenny M ; Stern, Peter L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-b852dd2132e2f2d533175b69cb5bab90d351867cd7a12e2cad3423840ba01c2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>E6 protein</topic><topic>Female</topic><topic>Genes, MHC Class I</topic><topic>Genes, MHC Class II</topic><topic>Genes, p53</topic><topic>Genetic Variation</topic><topic>histocompatibility antigen HLA</topic><topic>Human papillomavirus 16</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncogene Proteins, Viral - genetics</topic><topic>p53 gene</topic><topic>Papillomaviridae - classification</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus Infections - virology</topic><topic>Point Mutation</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic</topic><topic>Repressor Proteins</topic><topic>Sequence Analysis, DNA</topic><topic>Tumor Virus Infections - virology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brady, Claire S</creatorcontrib><creatorcontrib>Duggan-Keen, Margaret F</creatorcontrib><creatorcontrib>Davidson, Judith A</creatorcontrib><creatorcontrib>Varley, Jenny M</creatorcontrib><creatorcontrib>Stern, Peter L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of general virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brady, Claire S</au><au>Duggan-Keen, Margaret F</au><au>Davidson, Judith A</au><au>Varley, Jenny M</au><au>Stern, Peter L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters</atitle><jtitle>Journal of general virology</jtitle><addtitle>J Gen Virol</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>80</volume><issue>12</issue><spage>3233</spage><epage>3240</epage><pages>3233-3240</pages><issn>0022-1317</issn><eissn>1465-2099</eissn><abstract>Departments of Immunology 1 and Cancer Genetics 2 , Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK 3 Author for correspondence: Peter Stern. Fax +44 161 446 3109. e-mail pstern{at}picr.man.ac.uk Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.</abstract><cop>England</cop><pub>Soc General Microbiol</pub><pmid>10567656</pmid><doi>10.1099/0022-1317-80-12-3233</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1317
ispartof Journal of general virology, 1999-12, Vol.80 (12), p.3233-3240
issn 0022-1317
1465-2099
language eng
recordid cdi_proquest_miscellaneous_69293975
source MEDLINE; Microbiology Society; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Adult
Aged
Aged, 80 and over
E6 protein
Female
Genes, MHC Class I
Genes, MHC Class II
Genes, p53
Genetic Variation
histocompatibility antigen HLA
Human papillomavirus 16
Humans
Middle Aged
Neoplasm Staging
Oncogene Proteins, Viral - genetics
p53 gene
Papillomaviridae - classification
Papillomaviridae - genetics
Papillomavirus Infections - virology
Point Mutation
Polymerase Chain Reaction
Polymorphism, Genetic
Repressor Proteins
Sequence Analysis, DNA
Tumor Virus Infections - virology
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - virology
title Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A15%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20papillomavirus%20type%2016%20E6%20variants%20in%20cervical%20carcinoma:%20relationship%20to%20host%20genetic%20factors%20and%20clinical%20parameters&rft.jtitle=Journal%20of%20general%20virology&rft.au=Brady,%20Claire%20S&rft.date=1999-12-01&rft.volume=80&rft.issue=12&rft.spage=3233&rft.epage=3240&rft.pages=3233-3240&rft.issn=0022-1317&rft.eissn=1465-2099&rft_id=info:doi/10.1099/0022-1317-80-12-3233&rft_dat=%3Cproquest_cross%3E17479339%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17479339&rft_id=info:pmid/10567656&rfr_iscdi=true